AstraZeneca’s Evusheld significantly reduces risk of developing severe COVID-19
AstraZeneca's Evusheld (tixagevimab and cilgavimab) provided clinically and statistically significant…
AstraZeneca's Evusheld (tixagevimab and cilgavimab) provided clinically and statistically significant protection against progression to severe COVID-19 over placebo.